Human Bioequivalence Study of Liposomal Amphotericin B for Injection
Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
A single-center, randomized, open-label, single-dose, two-period, double-crossover study to evaluate the bioequivalence of liposomal amphotericin B for injection (test product) manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd. compared to the reference product (AmBisome) in healthy Chinese subjects. Secondary objectives include safety evaluation.
Phase:
NA
Details
Lead Sponsor:
Sichuan Huiyu Pharmaceutical Co., Ltd
Treatments:
Injections liposomal amphotericin B Long-Term Synaptic Depression